Business Description
![Kiora Pharmaceuticals Inc Kiora Pharmaceuticals Inc logo](https://static.gurufocus.com/logos/0C0000APFQ.png?14)
Kiora Pharmaceuticals Inc
NAICS : 325413
SIC : 2835
ISIN : US30233M1071
Description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 332.72 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-EBITDA | 0.04 | |||||
Interest Coverage | 519 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -1.83 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 64.7 | |||||
3-Year EPS without NRI Growth Rate | 68.9 | |||||
3-Year FCF Growth Rate | 68.4 | |||||
3-Year Book Growth Rate | -77.5 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.21 | |||||
9-Day RSI | 39.85 | |||||
14-Day RSI | 40.32 | |||||
6-1 Month Momentum % | -9.65 | |||||
12-1 Month Momentum % | -25.68 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 21.02 | |||||
Quick Ratio | 21.02 | |||||
Cash Ratio | 19.63 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -281.4 | |||||
Shareholder Yield % | -147.07 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | 38.93 | |||||
Net Margin % | 17.54 | |||||
FCF Margin % | 44.35 | |||||
ROE % | 19.25 | |||||
ROA % | 12.94 | |||||
ROIC % | 60.74 | |||||
ROC (Joel Greenblatt) % | 2456.86 | |||||
ROCE % | 12.64 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 2.62 | |||||
Price-to-Owner-Earnings | 7.19 | |||||
PS Ratio | 1.12 | |||||
PB Ratio | 0.38 | |||||
Price-to-Tangible-Book | 0.51 | |||||
EV-to-EBIT | -7.1 | |||||
EV-to-EBITDA | -6.97 | |||||
EV-to-Revenue | -1.11 | |||||
EV-to-Forward-Revenue | 0.66 | |||||
EV-to-FCF | -2.49 | |||||
Price-to-Net-Current-Asset-Value | 0.52 | |||||
Price-to-Net-Cash | 0.56 | |||||
Earnings Yield (Greenblatt) % | -14.08 | |||||
FCF Yield % | 53.3 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kiora Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 14.72 | ||
EPS (TTM) (€) | -13.352 | ||
Beta | 0.02 | ||
Volatility % | 40.56 | ||
14-Day RSI | 40.32 | ||
14-Day ATR (€) | 0.045467 | ||
20-Day SMA (€) | 3.7665 | ||
12-1 Month Momentum % | -25.68 | ||
52-Week Range (€) | 3.429 - 7.029 | ||
Shares Outstanding (Mil) | 2.92 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Kiora Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Kiora Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Kiora Pharmaceuticals Inc Frequently Asked Questions
What is Kiora Pharmaceuticals Inc(STU:7EY)'s stock price today?
The current price of STU:7EY is €3.77. The 52 week high of STU:7EY is €7.03 and 52 week low is €3.43.
When is next earnings date of Kiora Pharmaceuticals Inc(STU:7EY)?
The next earnings date of Kiora Pharmaceuticals Inc(STU:7EY) is .
Does Kiora Pharmaceuticals Inc(STU:7EY) pay dividends? If so, how much?
Kiora Pharmaceuticals Inc(STU:7EY) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |